Sector News

Mylan plans to shutter Meda's U.S. headquarters

November 2, 2016
Life sciences

Months removed from closing its $7 billion deal to buy Meda, Mylan is shuttering the U.S. headquarters of its new subsidiary in a move that’ll leave 94 employees without jobs.

Effective Dec. 31, Meda Pharmaceuticals’ office in Somerset, NJ, will be shut down, Mylan said in a statement. It’s a result of “ongoing integration efforts” and will mean 94 employees need to find new work, according to a WARN notice filed in New Jersey. Meda’s home base is near Stockholm, Sweden.

The HQ shutdown follows the August closing of Mylan’s Meda purchase, which came with pharma products, OTC drugs and generics. In announcing the deal in February, Mylan said Meda’s presence in China, Southeast Asia, Russia, the Middle East and Mexico would complement its operations in other emerging markets.

Things have changed dramatically for Mylan since it announced and closed the deal, as industry watchers know. Soon after Mylan brought Meda into the fold, controversy erupted about repeated price hikes for the company’s big-selling EpiPen. The company is under investigation by Congress and U.S. agencies, and it already ponied up $465 million to settle claims it overcharged Medicaid for the lifesaving epinephrine injector–admitting no fault–in an arrangement that one senator has called “unacceptable.”

EpiPen is expected to bring in much lower sales for Mylan in the coming years, partly because of an authorized generic Mylan is launching as a defense against its branded pricing criticism. That makes adding Meda even more important, because Mylan will need other products to pick up the slack.

Mylan is “working closely” with affected Meda employees to provide “severance, benefits and outplacement services during this transition,” according to a statement.

The company’s deal for Meda followed an intense, but ultimately fruitless, effort to snag generic rival Perrigo for $26 billion. Some market watchers said Mylan had overpaid for Meda, but Chairman Robert Coury said at the time the buy wouldn’t take his company out of the running for other M&A action.

Following the Meda deal announcement, Mylan shares fell about 17%. They had recovered some by the summer months, but the EpiPen scandal has taken a big toll, dragging shares down by about 25% since August.

By Eric Sagonowsky

Source: Fierce Pharma

comments closed

Related News

September 17, 2022

Novo Nordisk partners with Microsoft for AI-driven drug discovery

Life sciences

Novo Nordisk has signed a new strategic partnership with Microsoft to expedite the discovery and development of drugs leveraging big data and artificial intelligence (AI). Under the deal, Microsoft’s computational services, Cloud and artificial intelligence (AI) will be merged with the drug discovery, development and data science expertise of Novo Nordisk.

September 17, 2022

Bayer’s hunt for a new CEO is on, suggesting Werner Baumann could be headed for an early exit: report

Life sciences

Following years of push-and-pull over the German conglomerate’s top post, Bayer has quietly started a hunt for Baumann’s successor, Bloomberg News reported Tuesday, citing people close to the matter. The new CEO search may portend an early departure for Baumann, whose contract with Bayer isn’t set to expire until April 2024.

September 17, 2022

Bluebird CFO resigns ahead of gene therapy launch

Life sciences

Bluebird bio on Monday said its chief strategy and financial officer, Jason Cole, will leave the company this fall, marking the second time in less than a year the cash-strapped gene therapy developer will replace its top financial executive.